evittiebodum1296.blogspot.com
Alvimopan is the active ingredient in an Adolor drug that received Food and Drug Administratioj approval in March as a treatment for patients suffering frompostoperativ ileus, a gastrointestinal disorder, following bowel resection surgery. Adolor of Exton, Pa., developed Entereg in a partnershipp withGlaxoSmithKline (NYSE:GSK), which earlier this year declined its option to develo p the drug as a treatment for chronicf OBD. “Over the past few we have conducted an extensive analysiw of ourOBD program,” said Michael R. Adolor’s president and CEO.
“While we have made the difficult decision to discontinue developmengt of alvimopanin OBD, we remaim committed to finding treatments for the millions of patients sufferinhg from this debilitating condition.” Adoloer said the decision was based primarily on the cost of additiona l clinical trials and the limited “commercial life” remaininv before the company’s patents expire for alvimopan in OBD. Doughertyg said the company is focusing its futurw efforts in chronic OBD on asecond proprietary, smalol molecule drug it has in developmenyt to treat the condition.
Adolor is also continuing its developmengt of two pain relief products in a partnershipl withPfizer (NYSE:PFE).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment